Navigation Links
Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
Date:4/22/2008

certainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
2. Data Show SuperGens MP-470 is Safe in Humans
3. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
4. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
5. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
6. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... PITTSBURGH, April 2, 2012 Cohera Medical, a ... and sealants, announced today that its lead product, ... 2012 Medical Design Excellence Awards in the General ... The Medical Design Excellence Awards is the medical ...
... Healthcare, India,s leading provider of integrated healthcare services ... (NASDAQ: MASI ) jointly announce a ... access to Masimo,s full line of the most technologically ... solutions. As part of the new ...
Cached Medicine Technology:TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist 2TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist 3Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 2Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 3Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 4Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 5Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 6Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 7Fortis Healthcare Signs Agreement Giving India's Fastest-Growing Hospital Chain Access to Masimo's State-of-the-Art Noninvasive Patient Monitoring Solutions 8
(Date:4/24/2014)... 24, 2014 ,Take me out to the ballgame, ... kale chips. The more likely culprits include French fries, ... Unfortunately for children who play youth baseball, eating unhealthy ... weight problems, according to researchers at Wake Forest Baptist ... edition of Childhood Obesity , found that high-calorie ...
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
(Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
... obtained promising results in the development of a male ... almost 45 years after Schering developed the female contraceptive ... of an implanted hormonal capsule and an injection given ... by a slightly-built 53-year-old woman, Professor Ursula-Friederike Habenicht, who ...
... from a small group of patients can provide an ... by private health practitioners and their office practice, according ... Internal Medicine. ,Highly consistent and reliable data ... according to the present study in which approximately 13,000 ...
... and 250,000 early-stage glaucoma patients risk blindness due to lack ... Royal National Institute for the Blind (RNIB).// In an attempt ... Eyes' has been launched in the UK. ,Apart ... suffer from some form of visual impairment in the UK. ...
... put to sleep in separate beds to reduce the risk ... deaths as a consequence of parents sleeping together// with ... recent years according to a report, published in the Lancet. ... and those that sleep on their side or front face ...
... which were found to be an effective anti-depressant is ... researchers are not sure about the mechanism of serotonin ... Professor Gerard Aherm and team from Georgetown University Medical ... which has been found to be an effective antidepressant ...
... Medical School researchers have reason to cheer. ,A ... at the location. ,A gene responsible for a ... an incurable degenerative brain disease affecting movement and coordination. ... that it is caused by mutations in the protein, ...
Cached Medicine News:Health News:Male Contraceptive Pill Being Developed By Berlin Pharmaceutical 2Health News:Ataxia: a problematic disease's gene deciphered 2
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
... Med TruFlow™ Oxygen flowmeter with a Lexan®inner ... covering calibration and manufacturing defects. A wide ... most needs. Also available with all popular ... take-off and double unit configurations. Our extra ...
... with a Lexan®inner calibrated flow tube has ... defects. A wide range of configurations are ... with all popular inlet connections, a 50 ... configurations. Our extra large knob coupled with ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
Medicine Products: